CURRAX is a specialty pharmaceutical company focused on Neurology, Metabolic. Key products include ONZETRA XSAIL.
CURRAX's Key Drugs
CURRAX's core commercial portfolio centers on ONZETRA XSAIL, spanning Neurology and Metabolic — its most strategically important drugs approved in the last 15 years.
CURRAX's Recent FDA Approvals
New NDA/BLA approvals for CURRAX over the last two years — novel drugs only, excluding generics and label supplements.
CURRAX's Therapeutic Areas
CURRAX's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Metabolic, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CURRAX's Top Competitors
CURRAX's closest competitors by therapeutic-area and drug-target overlap include Eli Lilly, Roche, and SPECGX LLC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CURRAX Pipeline Snapshot
CURRAX has 2 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ONZETRA XSAIL leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2008-04-15
- Latest
- 2024-11-21
- Applications
- 3